Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor

Journal of Experimental Pharmacology

Volumn 8, Issue , 2016, Pages 11-19

  Singer, Jack W ^a   Al Fayoumi, Suliman ^a   Ma, Haiching ^b   Komrokji, Rami S ^c   Mesa, Ruben ^d   Verstovsek, Srdan ^e  

^a CTI BIOPHARMA CORP   (United States)

^b REACTION BIOLOGY CORPORATION   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

FMS like receptor tyrosine kinase 3; Hematologic malignancies; JAK2V617F; Janus kinase 2; Kinase analysis; Myelofibrosis

Indexed keywords

CD135 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; JANUS KINASE 2; PACRITINIB; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; IC50; INFLAMMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SOLID TUMOR;

EID: 84991585298     PISSN: None     EISSN: 11791454     Source Type: Journal    
DOI: 10.2147/JEP.S110702     Document Type: Article

References (54)

1. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19(49):5662-5679.
2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
3. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
4. William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11-(2-pyrrolidin- 1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-Triaza-Tetracyclo[19.3.1.1(2, 6).1(8, 12)]heptacosa-1(25), 2(26), 3, 5, 8, 10, 12(27), 16, 21, 23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem. 2011;54(13):4638-4658.
5. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011;25(11):1751-1759.
6. Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011;1(11):e44.
7. Verstovsek S, Deeg HJ, Odenike O, et al. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Proceedings of the 53rd Annual Meeting of the American Society of Hematology; December 10-13, 2011; Chicago, IL. Abstract 3082.
8. Verstovsek S, Odenike O, Scott B, et al. Phase 1 dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Proceedings of the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract 3905.
9. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Proceedings of the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract 311.
10. Younes A, Fanale M, Mclaughlin P, et al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biologic activity. Proceedings of the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract 588.
11. Younes A, Fanale M, Mclaughlin P, Copeland AR, Zhu J, De Castro Faria S. Phase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. Proceedings of the 53rd Annual Meeting of the American Society of Hematology; December 10-13, 2011; Chicago, IL. Abstract 2830.
12. Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Proceedings of the 53rd Annual Meeting of the American Society of Hematology; December 10-13, 2011; Chicago, IL. Abstract 282.
13. Verstovsek S, Mesa RA, Gotlib J, et al. Long-Term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT- I. Proceedings of the 55th Annual Meeting of the American Society of Hematology; December 7-10, 2013; New Orleans, LA. Abstract 2830.
14. Mesa RA, Egyed M, Szoke A, et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). Proceedings of the 2015 Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2015; Chicago, IL.
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
16. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type 1 cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102(52):18962-18967.
17. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062-1069.
18. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma. 2003;44(1):1-7.
19. Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs. 2006;11(1):153-165.
20. Steensma DP, McClure RF, Karp JE, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006;20(6):971-978.
21. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1039-1045.
22. Yee TW, Hastie TJ. Reduced-rank vector generalized linear models. Stat Model. 2003;3:15-41.
23. van der Loo MPJ. Distribution based outlier detection for univariate data, Discussion paper 10003. The Hague: Statistics Netherland; 2010.
24. Rhyasen GW, Bolanos L, Fang J, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013;24(1):90-104.
25. Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixido J, Costa C, Borrell JI. ALK and ROS1 as a joint target for the treatment of lung cancer: A review. Transl Lung Cancer Res. 2013;2(2):72-86.
26. Henderson MC, Gonzales IM, Arora S, et al. High-Throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells. Mol Cancer Res. 2011;9(6):724-732.
27. Polk A, Lu Y, Wang T, et al. Colony-stimulating Factor-1 receptor is required for nurse-like cell survival in chronic lymphocytic leukemia. Clin Cancer Res. Epub 2016 Jun 22.
28. Cleary MM, Thompson R, Mahmood S, et al. Pacritinib, a dual FLT3/JAK2 inhibitor, reduces IRAK-1 signaling in acute myeloid leukemia. Proceedings of the 57th Annual Meeting of the American Society of Hematology; December 5-8, 2015; Orlando, FL. Abstract 570.
29. JakafiR (ruxolitinib) tablets, for oral use [prescribing information]. Wilmington, DE: Incyte Corporation; 2011.
30. Gotlib J. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. Hematology Am Soc Hematol Educ Program. 2013;2013:529-537.
31. Gowin K, Emanuel R, Geyer H, Mesa RA. The new landscape of therapy for myelofibrosis. Curr Hematol Malig Rep. 2013;8(4):325-332.
32. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5.
33. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441-1445.
34. Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, Hantschel O. Specificity and mechanism-of-Action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia. 2014; 28(2):404-407.
35. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012;7(2):e30820.
36. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7):1192-1202.
37. Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015; 75(11):2187-2199.
38. Tefferi A. Ruxolitinib targets DCs: for better or worse? Blood. 2013; 122(7):1096-1097.
39. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol. 2009;10(4):356-360.
40. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208(6):1189-1201.
41. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell R, Baltimore D. NF-αB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A. 2011; 108(22):9184-9189.
42. Wang JQ, Jeelall YS, Ferguson LL, Horikawa K. Toll-like receptors and cancer: MYD88 mutation and inflammation. Front Immunol. 2014;5:367.
43. Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood. 2008;112(5):1960-1970.
44. McCleary MM, Thompson R, Mahmood S, et al. Pacritinib, a dual FLT3/JAK2 inhibitor, reduces Irak-1 signaling in acute myeloid leukemia. Proceedings of the 57th Annual Meeting of the American Society of Hematology; December 5-8, 2015; Orlando, FL. Abstract 570.
45. Ma Y, Rix LR, Zhang Q, et al. Pacritinib (PAC) synergistically potentiates azacitidine (5AZA) cytotoxicity in chronic myelomonocytic leukemia (CMML). Proceedings of the 57th Annual Meeting of the American Society of Hematology; December 5-8, 2015; Orlando, FL. Abstract 1658.
46. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-Associated macrophages. J Clin Invest. 2015;125(9):3365-3376.
47. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
48. Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of csf1r kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428-437.
49. Paniagua RT, Chang A, Mariano MM, et al. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther. 2010;12(1):R32.
50. Blonska M, Agarwal NK, Vega F. Shaping of the tumor microenvironment: Stromal cells and vessels. Semin Cancer Biol. 2015;34:3-13.
51. Borge M, Nannini PR, Morande PE, et al. CXCL12 is a costimulator for CD4T cell activation and proliferation in chronic lymphocytic leukemia patients. Cancer Immunol Immunother. 2013;62(1):113-124.
52. Borge M, Remes Lenicov F, Nannini PR, et al. The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406. J Immunol. 2014;193(6):3165-3174.
53. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466.
54. Knapper S, Grech A, Cahalin P, et al. An evaluation of the tyrosine kinase inhibitor pacritinib in patients with relapsed FLT-3 mutated acute myeloid leukaemia (the UK NCRI AML 17 study). Poster presented at: 21st Congress of the European Hematology Association; June 9-12, 2016; Copenhagen, Denmark. Abstract P184.